CEM Corporation and AmbioPharm enter into US partnership for GMP peptide production

CEM Corporation | September 16, 2021

CEM Corporation and AmbioPharm enter into US partnership for GMP peptide production
CEM Corporation and AmbioPharm, Inc. are pleased to announce the formation of a partnership to produce GMP peptides for the global market. The partnership includes the exclusive 1Use of CEM's microwave peptide synthesis technology on a large scale for the production of GMP peptides up to several kilograms using its own scalable reactors. The main advantages of this new relationship are the extremely short production times, the ability to efficiently produce more difficult peptide sequences, and the ability to incorporate green chemistry protocols. This partnership will enable the rapid and efficient production of new chemical peptide entities (NCEs) using the latest available technologies. With this agreement, AmbioPharm has started peptide synthesis at its North Augusta facility to better serve customers with fast microwave synthesis processes.

CEM's peptide production technology utilizes automated, large-scale microwave solid phase peptide synthesis systems (SPPS) that have been proven to improve peptide purity and minimize excess reagents. In addition, the CEM has developed proprietary coupling methods optimized for reactions at elevated temperatures 2 , a unique way to combine the coupling and deprotection reactions in a single step 3 , and established the use of more environmentally friendly solvents that are more accessible at elevated temperatures 4 . These unique technological advantages are licensed to AmbioPharm for GMP production.

AmbioPharm is a recognized leader in cGMP peptide production. The company employs more than 675 people and recently completed a major expansion of its headquarters in South Carolina, USA, adding nearly 56,000 square feet of additional peptide manufacturing capacity. The production plant has a cleaning capacity of up to 30 kg / batch and a freeze-drying capacity of up to 1,000 liters. The CEM Liberty Pro Synthesizer offers different reactor sizes (3, 8 and 15 liters) that allow the synthesis of batches from 5 g to 500 g of the final peptide.

Peptide-based drugs have enormous potential for the future and we are pleased to be able to help improve their production process. AmbioPharm is an ideal partner and we believe this relationship will enhance the opportunities for the manufacturing of peptide therapeutics.

- Michael J. Collins, Ph.D., President and CEO of CEM Corporation.

With the addition of CEM's microwave technology to our GMP peptide manufacturing options, we can offer even better service in terms of faster delivery for our partners' products and unique opportunities to make longer and more complex peptides accessible using microwave methods.

- Chris Bai, Ph.D., CEO of AmbioPharm Inc.

About CEM
CEM Corporation, a privately held company based in Matthews, North Carolina, is a leading provider of laboratory instruments. The company has subsidiaries in the UK, Germany, Italy, France, Japan and Singapore and a worldwide network of distributors. CEM designs and manufactures systems for life sciences, analytical laboratories and processing plants worldwide. The company's products are used in many industries, including the pharmaceutical, biotech, chemical and food industries, as well as academic research.

About AmbioPharm, Inc .
AmbioPharm, part of the Ambio Pharmaceuticals Group, is a leading, innovation-driven company that specializes in the development and manufacture of peptides and peptide-like products. AmbioPharm offers a comprehensive range of services and produces customized products for research, clinical development and commercial use for pharmaceutical and biotechnology companies worldwide. AmbioPharm operates internationally, has its headquarters in the USA, locations in Europe, the USA and Asia and has more than 14 years of experience and expertise.


the official journal of the Royal Pharmaceutical Society, which caters for Pharmacists and Pharmaceutical Scientists, is relaunched after 175 years from a 32-page weekly publication into a new 64-page monthly publication.

Related News


MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG

MindMed | February 15, 2021

MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As a component of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have just been combined by MindShift Compounds AG and related patent applications were documented by MindMed. MindMed plans to begin first-in-human Phase 1 clinical trials as ahead of schedule as Q1 2022 through its existing clinical preliminary stage for psychedelic and empathogenic compounds in Switzerland. The partnership on these initial targets will expand MindMed's current, grounded clinical pipeline with extra reinforcement and expansion compounds with comparative and possibly improved restorative properties. The connected combination intellectual property and drug technology will be possessed through and through by MindMed, and MindShift Compounds AG will give all intellectual property identified with the new psychedelic compounds only to MindMed. This partnership adds to MindMed's existing IP portfolio development endeavors in progress in collaboration with the University Hospital Basel's Liechti Lab for exemplary psychedelic compounds including LSD, MDMA, Psilocybin, MDMA-LSD combinations, personalized dosing technologies and a LSD Neutralizer technology, which depend on multiple clinical trials and long stretches of exploration led by the Liechti Lab. MindMed plans to work with the accomplished drug discovery group at MindShift Compounds AG to encourage extensively cover preclinical psychedelics investigation into novel compounds and hopes to continue to record a substantial number of licenses on countless novel substance matters, production innovations, and later clinical applications, allowing MindMed to additionally unite its leading situation in the in general psychedelic-medicine market as it moves these next-gen compounds into the clinic through advanced patient clinical trials. MindShift CEO, Dr. Felix Lustenberger, said "Our innovative psychedelic drug-discovery platform based in Switzerland is pioneering next-gen psychedelic compounds that complement in a synergistic pipeline approach the later-stage development work underway at MindMed. The compounds we are working on are typically derivatives or analogues of known substances with psychedelic properties, such as phenethylamines, tryptamines, and ergolines, and are therefore enhanced versions of both the established and classic psychedelic compounds such as mescaline, psilocybin, DMT, and LSD, as well as compounds with expected combined psychedelic-empathogenic effect profiles. These novel chemical structures, for example MDMA and LSD-like compounds, are designed and synthesized with expected ameliorated psychoactive properties and duration-of-effect profiles with potential added therapeutic benefits." About MindMed MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic-inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company's groundbreaking approach to developing the next generation of psychedelic-inspired medicines and therapies.

Read More

Apricus Health Partners with Medicare Advantage Plan Devoted Health and Full-Service Retail Pharmacy Liton Rx

Apricus Health | November 04, 2020

Apricus Health, an innovative healthcare company delivering high impact, relationship-based care, today announced two new partnerships that provide its members with extraordinary services. Medicare Advantage plan provider Devoted Health and full-service retail pharmacy Liton Rx are now partnering with the Apricus Health Network which is designed by Arizona physicians. "We are committed to helping our members with a range of quality services to improve health outcomes and significantly lower costs for patients and payers," said Dr. Kishlay Anand, CEO and co-founder of Apricus Health. "Our new partnerships with Devoted Health and Liton Rx, further that mission, with both organizations sharing our core value of emphasizing extraordinary customer service."

Read More


Rx-360 Launches New auditsPlus®

Rx-360 | June 10, 2021

Rx-360, a global pharmaceutical consortium committed to supply chain integrity and patient safety, is happy to announce the extension of our Audit Program. The release of the new Rx-360 auditsPlus database is the key driver of this growth. This interactive, user-friendly database will not only raise awareness of the Rx-360 Joint Audit Program®. Still, it will also provide Rx-360 program users with new and improved tools to minimize their audit burden. Rx-360's CEO, Jim Fries, stated, "Maintaining quality in pharmaceutical materials is an ever-increasing problem for the pharmaceutical sector. To maintain our commitment to patient safety, this new tool will provide users of our software with better insight into Rx-360 audits. It's another benefit we can provide the industry and our members." Jaye Greene, Rx-360's Head of Audit Operations and Quality, stated, "We are extremely excited to introduce the market to our new auditsPlus platform. The user experience has been greatly improved, and all of the Rx-360 Audit Programs are now easily accessible." About Rx-360 Rx-360, an international pharmaceutical supply chain consortium, was founded in 2009 to support an industry-wide commitment to maintaining patient safety via improved quality and authenticity across the supply chain. The organization's objective is to ensure patient safety by exchanging information and developing processes related to the integrity of the healthcare supply chain and the quality of products used in the supply chain. Rx-360 contains work streams relating to audit and sharing review reports, supply chain security, monitoring and reporting, Asia-focused activities, supplier-focused initiatives, and external relations, communications, and membership to fulfill this mission.

Read More


the official journal of the Royal Pharmaceutical Society, which caters for Pharmacists and Pharmaceutical Scientists, is relaunched after 175 years from a 32-page weekly publication into a new 64-page monthly publication.